Ticagrelor versus prasugrel in patients with acute myocardial infarction

Area of Science:

• Cardiology
• Pharmacology
• Clinical Research

Background:

• Ticagrelor and prasugrel are standard antithrombotic treatments for acute myocardial infarction (MI).
• Comparative clinical outcome data for potent P2Y12 inhibitors are scarce, particularly in East Asian populations.
• This study addresses the need for direct comparison of ticagrelor and prasugrel in acute MI patients.

Purpose of the Study:

• To evaluate and compare the clinical outcomes of ticagrelor versus prasugrel in patients with acute MI.
• To assess the net clinical benefit and individual components of effectiveness and safety.
• To provide evidence for treatment decisions in acute MI patients, especially in East Asian populations.

Main Methods:

• A nationwide cohort study using the Korean National Health Insurance database.
• 10,797 patients with acute MI receiving ticagrelor or prasugrel post-percutaneous coronary intervention (PCI) were analyzed.
• Propensity score matching was employed to create comparable groups for outcome analysis.

Main Results:

• The primary outcome (net clinical benefit: death, MI, stroke, or major bleeding) was similar between ticagrelor and prasugrel groups after propensity score matching (HR 0.949; 95% CI: 0.780-1.154).
• Effectiveness (death, MI, or stroke) and safety (major bleeding) composite outcomes also showed no significant differences between the two treatment groups.
• The study included a large cohort with a median follow-up of 1.8 years.

Conclusions:

• Ticagrelor and prasugrel demonstrate comparable net clinical benefits in acute MI patients undergoing PCI.
• No significant differences were observed in the risks of death, MI, stroke, or major bleeding between the two potent P2Y12 inhibitors.
• The findings support the use of either ticagrelor or prasugrel as effective antithrombotic strategies in this patient population.